- Home
- CRDL vs CIA Comparison
CRDL vs CIA Comparison
Compare CRDL & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- CIA
- Stock Information
- Founded
- CRDL 2017
- CIA 1969
- Country
- CRDL Canada
- CIA United States
- Employees
- CRDL N/A
- CIA N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- CIA Life Insurance
- Sector
- CRDL Health Care
- CIA Finance
- Exchange
- CRDL Nasdaq
- CIA Nasdaq
- Market Cap
- CRDL 140.1M
- CIA 140.5M
- IPO Year
- CRDL N/A
- CIA N/A
- Fundamental
- Price
- CRDL $2.57
- CIA $3.15
- Analyst Decision
- CRDL Strong Buy
- CIA
- Analyst Count
- CRDL 3
- CIA 0
- Target Price
- CRDL $9.00
- CIA N/A
- AVG Volume (30 Days)
- CRDL 339.1K
- CIA 72.5K
- Earning Date
- CRDL 08-12-2024
- CIA 11-04-2024
- Dividend Yield
- CRDL N/A
- CIA N/A
- EPS Growth
- CRDL N/A
- CIA N/A
- EPS
- CRDL N/A
- CIA 0.43
- Revenue
- CRDL N/A
- CIA $246,035,000.00
- Revenue This Year
- CRDL N/A
- CIA N/A
- Revenue Next Year
- CRDL N/A
- CIA $4.17
- P/E Ratio
- CRDL N/A
- CIA $7.24
- Revenue Growth
- CRDL N/A
- CIA 3.43
- 52 Week Low
- CRDL $0.66
- CIA $1.78
- 52 Week High
- CRDL $3.12
- CIA $3.69
- Technical
- Relative Strength Index (RSI)
- CRDL 69.28
- CIA 55.31
- Support Level
- CRDL $1.78
- CIA $3.00
- Resistance Level
- CRDL $1.96
- CIA $3.17
- Average True Range (ATR)
- CRDL 0.13
- CIA 0.19
- MACD
- CRDL 0.06
- CIA -0.01
- Stochastic Oscillator
- CRDL 95.68
- CIA 62.71
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. the Company derives its revenues principally from life insurance premiums earned for insurance coverages provided to insureds in our two operating segments and net investment income. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment.